CML Advocates Network participating at EHA-SWG 2018 Meeting

EHA logoThe European Hematology Association held the “EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis” on February 8-10, 2018 In Barcelona, Spain.

The scientific meeting covered all practical aspects of diagnosis of haematological disorders suspected when encountering leukocytosis or cytopenia, with a strong focus on morphology, pathology and flow cytometry.

toni1During three days, the hematological experts put under the spotlight very interesting topics as the following: Pre analytical and analytical considerations; Towards integrated diagnoses: basics of morphology, flow cytometry, cytogenetics and molecular karyotype, molecular technologies; Morphology of granulo-monocytopoiesis: normal, MDS, AML and MPN; Lymphopoiesis, leukemia and lymphoproliferative disorders; New drugs / therapeutic approaches and personalized medicine or Patient’s follow up: MRD and detection of the emergence of resistances.

On Friday morning, we were presenting the Chronic Myeloid Leukemia patients’ perspective with the collaboration of Toni Montserrat, CML patient advocate and leader of our Spanish member organisation “Pacientes LMC”. 

eha swg cml 1Our presentation was mainly concentrated on the CML patients issues trying to learn a better understanding of the CML patient's challenges in 2018.

Thereupon, we finished the presentation by sharing with the attending haematologists and clinicians two good examples of evidence-based CML patient advocacy such as the "LMC patients" survey on side effects and the study and scientific publication on Adherence of the CML Advocates Network.

For a complete overview of the scientific program of the EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis, click HERE.


We would like to thank the European Hematology Association Scientific Working Group the opportunity to represent one again the voice to the CML patient advocacy community in a scientific meeting as well as also thank the fantastic support our CML member advocates bring us worldwide.

To view the “Myeloproliferative disorders: Chronic Myeloid Leukemia from the patient’s perspective” presentation, please, click HERE.